The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of arteriovenous fistula nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease.

Renin-based assays and kits for quantitative measurement of hepcidin, preferably biologically active hepcidin-25. Also provided are treatment modalities for the management of blood pressure and methods of determining or monitoring a subject's hepcidin status, status of a hepcidin-related disorder, and/or response to treatment by employing the hepcidin assay or kit provides novel treatment modalities for the management of blood pressure.

Methods of using measured plasma renin activity assayed (PRA), plasma renin activity concentration (PRAC), active renin concentration (ARC), plasma renin activity concentration (PRAC) and/or active plasma renin concentration (APRC), pro-renin activity, (pro)-renin receptor (PRR) levels for diagnosing, prognosing, treating and monitoring heart failure (HF) or HF-associated conditions or other conditions that cause or are caused by altered (e.g., elevated) renin activity, pro-renin levels, PRR levels, PRC, APRC, and/or interaction of renin or pro-renin with PRR. These methods can be used for at-risk patients for personalized therapy of heart disease to reduce heart dysfunction progression, diminish HF, and prolong life. This technology stratifies patients with HF or those at risk for HF to determine the appropriate medication (agents that specifically interfere with plasma renin activity/pro-renin and/or PRR) or intervention and the appropriate dosage of medication to treat further HF progression.

An object of the present invention is to provide a sensor that can quickly and easily detect primary aldosteronism with a higher accuracy. The present invention provides a method of quickly detecting aldosterone or renin in a sample with high sensitivity, using a multiphase polymer fine particles having at least on a surface thereof two or more polymer phases formed by aggregation of two or more polymers, respectively, wherein aldosterone or renin covalently binds to a first polymer phase, and wherein a second polymer phase has a labeling substance.

The present invention provides a novel approach to the diagnosis, treatment and management of a fibrotic lesion by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations known to be associated with a fibrotic lesion, by modulation of the Renin-Angiotensin System.

The present invention relates to a method for determining, predicting or estimating the biological age of a subject, or for providing a measurement for use in determining, predicting or estimating the biological age of a subject or for predicting the presence or absence of at least one disease in a subject, predicting the risk of a subject of having or developing at least one disease; and/or predicting the risk of mortality of a subject. This invention also relates to a device for determining the presence and/or amount of each biomarker in a set of biomarkers; a set of probes for determining the presence or amount of a set of biomarkers, and the use of such device and/or probes in any of the above methods. Also provided is a biomarker testing kit for use in a method as described herein and a computer-readable storage medium or a computer program comprising computer-executable instructions and associated method.